← Back to Search

PET Scans for Brain Tumors

Phase < 1
Recruiting
Led By Simone Krebs, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
Adults ≥ 18 years old
Must not have
Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to determine if a type of imaging test called 68Ga-PSMA-11 PET/CT can accurately measure tumor activity in participants with high-grade glioma or brain metastases.

Who is the study for?
This clinical trial is open to individuals with high-grade gliomas or brain metastases. Participants must be suitable for PET/CT scans and have a type of brain tumor that might show activity on these scans.
What is being tested?
The study is testing the effectiveness of a special imaging scan called 68Ga-PSMA-11 PET/CT in detecting active cancer cells in patients with certain types of aggressive brain tumors or secondary brain cancers.
What are the potential side effects?
As this trial involves diagnostic imaging, side effects may include discomfort at the injection site, allergic reactions to the tracer, and exposure to radiation typical for PET/CT scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have or am suspected to have a high-grade glioma or brain metastases from another cancer.
Select...
I am 18 years old or older.
Select...
I can take care of myself but might not be able to do active work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any serious illnesses that would stop me from following the study's requirements.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess range of tumor uptake of 68Ga-PSMA-11 in participants

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with high-grade gliomaExperimental Treatment1 Intervention
Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,972 Previous Clinical Trials
597,698 Total Patients Enrolled
Simone Krebs, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
30 Total Patients Enrolled
~20 spots leftby Jan 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top